| In millions, except per share items | Jan-31-23 | Oct-31-22 | Apr-30-22 | Jan-31-22 | Oct-31-21 | Jul-31-21 | Apr-30-21 | Jan-31-21 |
| | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q |
| REVENUE | | | | | | | | |
| Rental – Third Party | 0.0 | 0.0 | 0.2 | 0.0 | 0.0 | 0.2 | 0.2 | 0.2 |
| Rental – Related Party | 0.0 | 0.0 | 0.5 | 0.0 | 0.0 | 0.5 | 0.5 | 0.5 |
| Other – Related Party | | | | | 0.1 | | 0.1 | 0.1 |
| Total revenue | 0.1 | 0.1 | 0.9 | 0.1 | 0.2 | 1.0 | 1.0 | 1.0 |
| Total revenue growth | -5.4% | -63.4% | -11.6% | -92.3% | -81.9% | -21.9% | -19.1% | -22.4% |
| COSTS AND EXPENSES | | | | | | | | |
| General and administrative | 2.1 | | | 1.7 | | | | |
| Research and development | 2.2 | 2.1 | 1.4 | -3.3 | 2.2 | 1.6 | 1.3 | 1.6 |
| Depreciation and amortization | 0.0 | 0.0 | 0.4 | 0.0 | 0.0 | 0.4 | 0.2 | 0.4 |
| Provision for loss on receivable from Cornerstone Pharmaceuticals pursuant to line of credit | | | | | 25.0 | | | |
| Provision for losses on related party receivables | | | | | 10.3 | | | 7.0 |
| Loss from operations | -4.3 | -5.1 | -4.9 | -1.6 | -49.5 | -13.0 | -3.5 | -10.8 |
| Operating margin | -6084.3% | -7345.7% | -555.1% | -2160.8% | -25936.1% | -1344.2% | -351.4% | -1127.9% |
| Interest expense | | | -0.4 | | 0.0 | | 0.0 | |
| Interest income | 0.6 | 0.2 | 0.1 | | 0.2 | | 0.0 | |
| Impairment of investments - Other Pharmaceuticals | -0.1 | -0.2 | | | | | | |
| Impairment of cost method investment - Cornerstone Pharmaceuticals | | | | | -79.1 | | | |
| Realized gain on available-for-sale securities | 0.1 | 0.0 | | | | | | |
| Unrealized gain (loss) on investments - Hedge Funds | 0.4 | | | -0.5 | | | | |
| Loss from continuing operations before income taxes | -3.2 | -5.2 | -5.5 | -2.1 | -128.3 | -12.5 | -2.7 | -8.3 |
| Provision for income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.6 | 0.0 | 0.0 | 0.0 |
| Equity in loss of RP Finance | | | | | -0.6 | 0.1 | 0.1 | 0.1 |
| Consolidated net loss from continuing operations | -3.3 | -5.2 | -5.5 | -2.1 | -128.9 | -12.6 | -2.7 | -8.2 |
| |
| Discontinued Operations (Note 3) | | | | | | | | |
| Loss from discontinued operations related to 520 Property | -0.2 | -0.1 | | -0.5 | -0.5 | | | |
| Gain on disposal of 520 Property | | 6.8 | | | | | | |
| (Loss) income from discontinued operations | -0.2 | 6.7 | | -0.5 | -0.5 | | | |
| Consolidated net loss | -3.4 | 1.5 | -5.5 | -2.6 | -129.4 | 12.3 | -2.7 | -8.2 |
| Net loss attributable to noncontrolling interests | -0.2 | -0.1 | 0.0 | -0.2 | -17.4 | 0.2 | -0.1 | -0.1 |
| Net loss attributable to Rafael Holdings, Inc. | -3.3 | 1.6 | -5.5 | -2.3 | -112.0 | 12.2 | -2.6 | -8.2 |
| |
| OTHER COMPREHENSIVE LOSS | | | | | | | | |
| Consolidated net loss | -3.4 | 1.5 | -5.5 | -2.6 | -129.4 | 12.3 | -2.7 | -8.2 |
| Unrealized gain on available-for-sale securities | 0.3 | 0.1 | | | | | | |
| Foreign currency translation adjustment | 0.0 | 0.0 | -0.2 | 0.1 | 0.0 | | 0.0 | 0.0 |
| |
| Total comprehensive loss | | | | | | | | |
| Comprehensive loss attributable to noncontrolling interests | | | | | | | | |
| Total comprehensive loss attributable to Rafael Holdings, Inc. | -3.0 | 1.7 | -5.8 | -2.1 | -129.4 | -12.5 | -2.6 | -8.1 |
| |
| Loss per share attributable to common shareholders | | | | | | | | |
| Continuing operations - basic and diluted (in Dollars per share) | 0.0 | 0.0 | | 0.0 | 0.0 | | | |
| Discontinued operations - basic and diluted (in Dollars per share) | 0.0 | 0.0 | | 0.0 | 0.0 | | | |
| |
| Total basic and diluted (loss) per share (in Dollars per share) | ($0.14) | $0.07 | ($0.28) | ($0.12) | ($5.91) | ($0.74) | ($0.15) | ($0.50) |
| |
| Weighted average number of shares used in calculation of loss per share | | | | | | | | |
| Basic and diluted (in Shares) | 23.2 | 23.0 | 19.8 | 19.7 | 18.9 | 16.5 | 16.7 | 16.2 |